https://www.selleckchem.com/pr....oducts/DMXAA(ASA404)
To explore the feasibility of a neuroprotection trial in prodromal synucleinopathy, using idiopathic rapid eye movement sleep behavior disorder (iRBD) as the target population and I-FP-CIT-SPECT as a biomarker of disease progression. Consecutive iRBD patients were randomly assigned to a treatment arm receiving selegiline and symptomatic rapid eye movement sleep behavior disorder treatment, or to a control arm receiving symptomatic treatment only. Selegiline was chosen because of a demonstrated neuroprotection effect in animal mode
Curtir
Comentario
Compartilhar
